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ASM = airway smooth muscle; BAL = bronchoalveolar lavage; COX = cyclooxygenase; ECM = extracellular matrix; FGF = fibroblast growth factor;
GM-CSF = granulocyte/macrophage-colony stimulating factor; IFN = interferon; IGF = insulin-like growth factor; IL = interleukin; LIF = leukaemia
inhibitory factor; 5-LO = 5-lipoxygenase; LT = leukotriene; MCP = monocyte chemotactic protein; MHC = major histocompatibility complex; NO =
nitric oxide; PDGF = platelet-derived growth factor; PG = prostaglandin; RANTES = regulated on activation, normal T cell expressed and secreted;
TGF = transforming growth factor; Th = T helper cells; TNF-α = tumour necrosis factor-α; TX = thromboxane.
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Introduction
Inflammation of the airway wall is a central characteristic of
asthma [1]. Airborne allergens often lead to an accumula-
tion of eosinophils, lymphocytes (predominantly CD4
type), mast cells and macrophages, resulting in an inflam-
matory reaction in the mucosa. Neutrophil numbers can
increase during an exacerbation. The release of mediators
from these inflammatory cells has been proposed to con-
tribute directly or indirectly to changes in airway structure
and function.
Important structural changes of inflamed airways include
epithelial cell shedding, basement membrane thickening,
goblet cell hyperplasia (increase in cell number) and
hypertrophy (increase in cell size), as well as an increase
in airway smooth muscle (ASM) content [2]. These struc-
tural changes consequently form the basis for airway
remodelling, a phenomenon believed to have profound
consequences for airway function [3]. Bronchial vascular
remodelling, with an increase in size and number of blood
vessels as well as vascular hyperaemia have been pro-
posed as contributing factors in airway wall remodelling in
patients with chronic asthma.
The ASM has been typically described as a contractile
tissue, responding to pro-inflammatory mediators and
neurotransmitters by contracting, and responding to
bronchodilators by relaxing. It has recently been recognised,
however, that the synthetic function of ASM cells may be
related to the perpetuation and intensity of airway wall
inflammation. A number of recent studies have shown that
ASM cells are also a rich source of biologically active
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cytokines, chemokines and growth factors, which may mod-
ulate airway inflammation through chemotactic, autocrine or
paracrine effects. The expression of adhesion molecules
and the release of cyclooxygenase (COX)-derived products
by ASM cells may also influence inflammatory processes in
the airways. In this review, we discuss the role of ASM cells
in the regulation of airway inflammation and its contribution
to subsequent airway wall remodelling.
Inflammatory mediators in the airways
Inflammatory mediators may be generated by resident
cells within the airways and lungs, as well as by cells that
have migrated into the airway from the circulation. The
release of pro-inflammatory mediators can induce airway
hyper-reactivity and airway wall remodelling [4–6]. Addi-
tionally, these mediators may further help in the recruit-
ment and activation of other inflammatory cells, thus
augmenting the inflammatory cascade. Potential sources
of pro-inflammatory mediators in inflamed airways include
eosinophils, epithelial cells, lymphocytes, mast cells,
macrophages, neutrophils and platelets, as summarised in
Table 1. The effects of a number of these individual media-
tors on ASM cell synthetic functions have recently been
described. It seems unlikely that one particular mediator is
solely responsible for the perpetuation of airway inflamma-
tion; perhaps a network of mediators contributes to the
inflammatory processes.
Cytokine production by human ASM
Chronic airway inflammation is orchestrated and regulated
by a complex network of cytokines, and these cytokines
have numerous and divergent biological effects. ASM
cells have been shown to be capable of producing a
number of cytokines (Th1 type: IL-2, granulocyte/
macrophage-colony stimulating factor [GM-CSF], IFN-γ,
IL-12; and Th2 type: IL-5, IL-6, GM-CSF), which then have
the potential to influence airway inflammation and the
development of airway remodelling (Table 2).
Secretion of Th1-type cytokines by ASM cells
In a study by Hakonarson et al., it was demonstrated that
sensitised ASM cells could express the Th1-type cytokines
IL-2, IL-12 and IFN-γ hours after the initial upregulation of
Th2-type cytokines [7]. ASM cell-derived IL-2 and IFN-γ
may play a protective role in the airway considering the
results published by Hakonarson et al., whereby exoge-
nous IL-2 or INF-γ attenuated atopic serum-induced ASM
hyper-responsiveness to acetylcholine. IFN-γ may also play
a protective role in atopic asthma by functionally antago-
nising IL-4-driven immunoglobulin isotype switching to IgE
synthesis.
Inhibition of the proliferation of Th2 cells, mast cells and
eosinophils or promotion of the differentiation of Th0 cells
into those expressing a Th1 phenotype may also be con-
sidered protective in asthmatic airways. Low levels of IFN-
γ have been detected in the bronchoalveolar lavage (BAL)
fluid of patients with stable asthma, whereas the levels of
mRNA for IFN-γ were not elevated in BAL fluid from
patients with mild asthma [8]. This observation supports
the notion that the pro-asthmatic state reflects an imbal-
ance between Th1-type and Th2-type cytokine production.
Table 1
Cellular sources of inflammatory mediators in inflamed airways
Source Inflammatory mediators Reference
Eosinophil MBP, EDN, ECP, EPO [9,34,78]
LTC4, PAF, O2–, MMP-9
IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, TGF-β, GM-CSF, TNF-α, MIP-1α, TIMP-1, PDGF
Epithelium IL-1β, IL-6, IL-8, GM-CSF, ET-1, FGF, RANTES, MCP, MIP-1α, TIMP-1, TNF-a, TGF-β, PDGF [9,48]
Macrophage IL-1, IL-6, IL-10, GM-CSF, TNF-α, prostaglandins, TXs, LTs, PAF, FGF, ET-1, TGF-β, PDGF, MCP [9,48]
Mast cell IL-1, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-13, GM-CSF, TNF-α, TGF-β, histamine, tryptase, [9,34]
chymase, bradykinin, prostaglandins, PAF, LTs
Neutrophil Myeloperoxidase, lysozyme, LTA4, LTB4, IL-1β, IL-6, IL-8, prostaglandins, PAF,TXA2, TNF-α, TGF-β, [34]
elastase, collagenase, MMP-9
Th1 lymphocyte IL-2, IL-3, GM-CSF, IFN-γ, TNF-α, TNF-β [9]
Th2 lymphocyte IL-3, IL-4, IL-5, IL-6, IL-10, IL-13, GM-CSF [9]
Plasma 5-HT, angiotensin II [79,80]
ECP, Eosinophil cationic protein; EDN, eosinophil derived neurotoxin; EPO, eosinophil peroxidase; ET, endothelin; FGF, fibroblast growth factor;
GM-CSF, granulocyte/macrophage-colony stimulating factor; 5-HT, 5-hydroxytryptamine; IFN, interferon; IL, interleukin; LT, leukotriene; MBP, major
basic protein; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; MMP-9, matrix metalloprotease-9; PAF, platelet
activating factor; PDGF, platelet-derived growth factor; RANTES, regulated on activation, normal T cell expressed and secreted; TGF-β,
transforming growth factor-β; TIMP-1, tissue inhibitor metalloprotease; TNF-α, tumour necrosis factor-α; TX, thromboxane.
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In patients with acute severe asthma, however, serum
levels of IFN-γ were found to be elevated [9].
Secretion of Th2-type cytokines by ASM cells
The pro-inflammatory cytokines IL-1β and tumour necrosis
factor-α (TNF-α) are found in exaggerated quantities in the
BAL fluid from symptomatic asthmatics and can cause
airway hyper-responsiveness and eosinophilia [10]. Cul-
tured human ASM cells stimulated with IL-1β or TNF-α
release IL-6 and GM-CSF [11–16].
IL-6 is a pleiotropic cytokine with a number of pro-inflam-
matory properties that could be relevant to the develop-
ment and perpetuation of airway inflammation during
asthma. These properties include mucus hypersecretion,
the terminal differentiation of B cells into antibody-produc-
ing cells, upregulation of IL-4-dependent IgE production
and stimulation of cytotoxic T-cell differentiation, as well as
differentiation of immature mast cells. Possible anti-inflam-
matory properties of IL-6 include the inhibition of
macrophage production of inflammatory cytokines and
reduced airway responsiveness to methacholine.
GM-CSF has been implicated in the activation, prolifera-
tion and subsequent survival of infiltrating inflammatory
cells such as neutrophils and eosinophils. Elevated levels
of GM-CSF have been found in airway biopsies from
asthma patients, and its overexpression is associated with
pulmonary eosinophilia and fibrosis. Increased levels of
IL-6 and GM-CSF have also been detected in the BAL
fluid of asthmatic subjects [10]. IL-6 and GM-CSF expres-
sion by human ASM cells can be decreased by treatment
Available online http://respiratory-research.com/content/3/1/11
Table 2
Airway smooth muscle (ASM) cell-derived inflammatory cytokines, their target cells and effects
Cytokine Target Effect Reference
IL-1 ASM IL-6, IL-11, LIF, GM-CSF, MCP, eotaxin, PDGF, PGE secretion↑ [11,13,21,26,31,32]
Eosinophil Recruitment
IL-2 T cell Proliferation↑ [9]
Eosinophil Recruitment
IL-5 Eosinophil, mast cell, T cells Recruitment, activation↑, survival↑ [7,9]
ASM Responsiveness↑
IL-6 mθ Proliferation↓ [9]
Goblet cell Proliferation↑, mucus secretion↑
B cell Differentiation to plasma cell
Cytotoxic T cell Differentiation
Fibroblast Activation
IL-11 ASM Proliferation↑ [81,82]
mθ, monocyte Secretion↓ TIMP-1
IL-12 T cell Proliferation↑ [9]
IFN-γ Th2 cells Proliferation↓ [9,62]
Th0 cells → Th1
B cells IL-4-driven immunoglobulin isotype switching to IgE synthesis↓, proliferation↓
Eosinophil, mast cell MCP, PGE secretion↑
ASM MHC II expression
Activation, secretion↑
mθ ICAM-1↑
LIF Monocytes IL-8 secretion↑ [83,84]
Neurons Phenotype regulation, tachykinin release↑
mθ Differentiation
↑, Increase; ↓, decrease; →, unchanged. GM-CSF, Granulocyte/macrophage-colony stimulating factor; ICAM-1, intercellular adhesion molecule-1;
IFN, interferon; IL, Interleukin; LIF, leukaemia inhibitory factor; MCP, monocyte chemotactic protein; MHC, major histocompatibility complex; mθ,
macrophage; PDGF, platelet-derived growth factor; PGE, prostaglandin E; Th, T helper cells; TIMP-1, tissue inhibitor metalloprotease.
with the glucocorticosteroid dexamethasone [11–13],
suggesting that these cells may be an important target cell
for the anti-inflammatory effects of steroids in asthma
therapy [17].
BAL fluid samples isolated from atopic asthmatic patients
also reveal significantly increased levels of IL-5 [18]. This
cytokine is predominantly produced by infiltrating T cells in
asthmatic airways, and possibly by mast cells [8], and is
involved in the recruitment and subsequent activation of
mast cells and eosinophils that are characteristic of asth-
matic airway inflammation. IL-5 promotes mobilisation of
eosinophils from the bone marrow. A recent study,
however, has shown that human bronchial smooth muscle
cells in culture, when passively sensitised with serum from
patients with atopic asthma, can also express and secrete
IL-5. Treatment of naive ASM with exogenous IL-5 potenti-
ated its responsiveness to acetylcholine, suggesting that
this Th2 cytokine may be involved in the pathobiology of
asthma [7]. It should be borne in mind, however, that the
concentrations of IL-5 in these experiments were signifi-
cantly higher than the concentrations of IL-5 secreted by
the sensitised ASM cells into the culture medium.
Passive sensitisation of ASM cells in culture also induced
the synthesis and release of GM-CSF, IL-1β, IL-6 and IL-8
[7,15,19,20]. The release and subsequent autocrine
action of IL-1β is of particular interest considering its pro-
inflammatory effects mentioned earlier. The timing and
order of secretion of Th1 and Th2 cytokines by ASM cells
may be an important intrinsic regulatory mechanism. The
question remains whether this mechanism is defective in
ASM cells in asthmatic airways, thereby leading to an
exaggerated Th2 response.
Secretion of other cytokines by ASM cells
IL-11 and leukaemia inhibitory factor (LIF) are classified as
IL-6-type cytokines and they are produced by fibroblasts
and epithelial cells of the airways. IL-11 has a variety of
biological properties including the stimulation of tissue
inhibitor of metalloproteinase-1, inhibition of macrophage/
monocyte-derived cytokine production and inhibition of
nitric oxide (NO) production. A reduction in NO produc-
tion in the asthmatic airway could have deleterious conse-
quences for airway calibre considering the fact that
endogenous NO is partly responsible for maintaining ASM
tone. On the contrary, a reduction in NO production (by
inducible NO synthase) in the asthmatic airway could
reduce tissue damage and inflammation, depending on
the relative amount of NO produced. LIF is a multifunc-
tional cytokine with the ability to regulate macrophage dif-
ferentiation. It also acts as a potent regulator of neuronal
phenotype by modulating sympathetic neurones to adopt
a cholinergic phenotype. LIF can also enhance neuronal
tachykinin production and differentially regulate the
expression of neural muscarinic receptors.
All of these mechanisms can alter airway function and,
therefore, may become relevant to the pathogenesis of
inflammatory airway diseases. A study by Elias et al.
showed that transforming growth factor-β1 (TGF-β1) and/or
IL-1α could stimulate human ASM cells to express and
release IL-11, IL-6 and LIF. Respiratory syncytial virus and
para-influenza virus type 3 were also potent stimulators of
IL-11 by human ASM cells [21]. These viruses are known
to be important triggers of asthma exacerbations [22].
Chemokine production by human ASM
A complex network of chemokines also regulates chronic
airway inflammation. Chemokines are 8–10 kDa proteins
that have been divided into subfamilies on the basis of the
position of their cysteine residues located near the N-ter-
minus of the protein. These mediators have numerous and
divergent biological effects including leukocyte trafficking,
degranulation of cells, angiogenesis, haematopoiesis and
immune responses [23]. Chemokines produced and
secreted by ASM cells may amplify the chemokine signal
generated by the infiltrating inflammatory cells in the
airway, thereby augmenting the recruitment of eosinophils,
neutrophils, monocytes and lymphocytes to the airway
(Table 3). The accumulation of these inflammatory cells
subsequently contributes to the development of airway
hyper-responsiveness, local inflammation and tissue injury
through the release of granular enzymes and other
cytokines. Eosinophils are also known to produce growth
factors such as TGF-β1 and platelet-derived growth factor
(PDGF). These growth factors can induce proliferation of
fibroblasts and smooth muscle cells in vitro, possibly
leading to the observed increase in smooth muscle mass
in the asthmatic airway.
CC chemokines
The CC chemokines (or beta subfamily) have two juxta-
posed cysteine residues. RANTES (regulated on activation,
normal T cell expressed and secreted) is a potent chemoat-
tractant for monocytes, T lymphocytes and eosinophils
[23], and is produced by inflammatory cells and epithelial
cells of the airways. Increased levels of RANTES in the
BAL fluid and the bronchial mucosa of allergic asthmatic
patients have been measured [24]. Several studies have
demonstrated that human ASM cells are also capable of
expressing and secreting biologically active RANTES fol-
lowing stimulation with TNF-α or IL-1β [14,25,26]. Stimula-
tion of human ASM cells with IFN-γ in combination with
TNF-α and/or IL-1β potentiated this effect, possibly via
upregulation of IFN-γ receptor expression [25]. Treatment
of the cells with dexamethasone inhibited expression of
RANTES mRNA and inhibited secretion of RANTES
protein. The Th2-type cytokine IL-10, however, failed to
attenuate RANTES mRNA expression but did inhibit secre-
tion of RANTES induced by a combination of IFN-γ and
TNF-α. IL-10 could not inhibit TNF-α-induced RANTES
secretion from cultured ASM cells [25,26].
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The spectrum of target cells for the monocyte chemotactic
proteins (MCPs) MCP-1, MCP-2, MCP-3, MCP-4 and
MCP-5 includes monocytes, lymphocytes, eosinophils,
basophils, dendritic cells and natural killer cells. Cellular
sources of MCPs include lymphocytes, monocytes, alveo-
lar macrophages and bronchial epithelial cells. Increased
levels of mRNA and protein encoding MCPs have been
detected in BAL fluid and bronchial biopsies of patients
with asthma [24,27–30]. Work published by two groups
describes the expression and secretion of MCP-1, MCP-2
and MCP-3 by human ASM cells treated with the pro-
inflammatory cytokines TNF-α, IFN-γ, IL-1β or IL-1α,
although induction patterns between chemokine mRNA
expression after stimulation with the individual cytokines
differed [26,31]. Furthermore, Pype et al. show that dex-
amethasone inhibited MCP mRNA expression and protein
secretion in human ASM cells, whereas IL-10 had no
effect on the expression [26]. No real data have so far
been published showing the secretion of MCP-4, MCP-5
or the weak eosinophil attractant macrophage inflamma-
tory protein-1α by ASM cells.
Eotaxin is a potent chemoattractant for eosinophils,
basophils and Th2-like T lymphocytes. It cooperates with
IL-5 in vivo to induce eosinophil recruitment; IL-5 pro-
motes mobilisation of eosinophils from the bone marrow,
whereas eotaxin recruits eosinophils in the tissue. More-
over, eotaxin has the ability to induce mast cell growth.
Eotaxin is highly expressed by epithelial cells and inflam-
matory cells in asthmatic airways, and has been measured
in increased quantities in BAL fluid from asthmatic sub-
jects [23,24,29]. Two recent reports demonstrated that
human ASM cells expressed eotaxin mRNA and protein
following TNF-α and/or IL-1β stimulation [32,33]. Neither
dexamethasone nor IL-10 inhibited the expression of
mRNA encoding eotaxin, although IL-10 did inhibit the
release of eotaxin protein into the culture medium, sug-
gesting inhibition at a translational and/or post-transla-
tional level [32].
CXC chemokines
The CXC chemokines (or alpha subfamily) have two cys-
teine residues separated by an amino acid residue located
near the N-terminus of the protein. IL-8 is an example of a
CXC chemokine, and it is a potent chemoattractant and
activator for neutrophils as well as a chemoattractant for
eosinophils [6,34]. IL-8 is produced by inflammatory cells
and epithelial cells in the airways and has been found to
be elevated in the BAL fluid from asthma patients [35].
There are several studies demonstrating that human ASM
cells stimulated with TNF-α, IL-1β or IL-1α can express
and secrete IL-8 in vitro [15,31,36]. The study carried out
by Herrick et al. also showed that atopic/asthmatic serum
stimulates ASM cells to express mRNA encoding IL-8
[15]. Pang and Knox showed that bradykinin also stimu-
lates the production of IL-8 in human ASM cells [37]. Both
dexamethasone and IL-10 can inhibit the release of IL-8
protein into the culture medium [36].
Growth factor production by human ASM
ASM cells are also a potential source of growth factors
that have been implicated in airway wall thickening and
may indirectly influence airway inflammation (Table 4).
Fibroblast growth factor-2 (FGF-2) is produced by fibro-
blasts and vascular smooth muscle cells in vitro and is
described as mitogenic for cells of mesenchymal origin
Available online http://respiratory-research.com/content/3/1/11
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Table 3
Airway smooth muscle cell-derived chemokines, their target cells and effects
Chemokine Target Effect Ref
IL-8 Neutrophil Recruitment, activation↑ [34]
Eosinophil, T cell Recruitment
Eotaxin Eosinophil, T cells, basophil Recruitment [23,24,29,34,85,86]
Mast cell Induces growth
RANTES Eosinophil, T cells, monocytes Recruitment [23,24,29,34]
GM-CSF Eosinophil, mq, monocyte Recruitment, activation↑, proliferation↑ [34]
Neutrophil Survival↑
MCP Monocytes, lymphocytes, eosinophil, basophil, Recruitment, activation↑ [23,24,29]
dendritic cells, NK cells
mθ IL-1 secretion↑
MIP-1a Eosinophil, NK, T cells, monocytes, mast cell, basophil Recruitment, activation↑ [23,24]
↑, Increase; GM-CSF, granulocyte/macrophage-colony stimulating factor; IL, interleukin; MCP, monocyte chemotactic protein; MIP, macrophage
inflammatory protein; mθ, macrophage; NK, natural killer; RANTES, regulated on activation, normal T cell expressed and secreted.
[38–40]. Increased concentrations of FGF-2 have been
measured in the BAL fluid from asthmatic patients [6].
Rödel et al. suggest that this increase in FGF-2 in the
airways may be the result of chronic Chlamydia pneumo-
niae infections, supported by their in vitro experiments
showing that C. pneumoniae infection of human ASM
cells significantly increased production of FGF-2 and IL-6
[41]. FGF-2 is released after host-cell lysis and may then
act as a paracrine growth factor for neighbouring ASM
cells, as well as upregulating the expression of interstitial
collagenase, which mediates extracellular matrix (ECM)
turnover. This turnover may support the proliferation of
ASM cells in vivo, leading ultimately to airway remodelling.
TGF-β1 can be produced in the lung by a variety of cells,
including macrophages, platelets, eosinophils, mast cells,
activated T lymphocytes and epithelial cells, and it is
detected in exaggerated quantities in asthmatic BAL fluid
before and after antigen challenge [6]. It is an extremely
potent stimulus for the synthesis of ECM components
such as collagen and fibronectin leading to tissue fibrosis
and it can also inhibit ASM NO production, potentially
resulting in a loss of control of airway calibre. The modula-
tion of smooth muscle cell β-adrenergic receptor number
and function by TGF-β1 can attenuate the effects of
endogenous catecholamines or therapeutically applied β-
adrenergic agonists.
In some studies, TGF-β1 expression correlates with base-
ment membrane thickness and fibroblast number and/or
disease severity. Black et al. showed that ASM cells
secreted latent TGF-β1 into the culture medium [42].
Results from our laboratory demonstrated that human
bronchial ASM cells express and secrete significant
amounts of TGF-β1 in response to the potent vasocon-
strictor angiotensin II [43]. The production of TGF-β1 co-
incided with ASM cellular hypertrophy, suggesting an
autocrine effect of TGF-β1 on ASM cell phenotype. Work
by Cohen et al. demonstrates that TGF-β1 can also modu-
late epidermal growth factor-induced DNA biosynthesis in
human tracheal ASM cells [44]. Several studies show,
however, that exogenous TGF-β1 can also stimulate
bovine ASM cell mitogenesis [45].
Activated macrophages, eosinophils, epithelial cells,
fibroblasts and smooth muscle cells produce PDGF. De et
al. reported that ASM cells in culture could also express
PDGF following IL-1β stimulation [46]. PDGF is a highly
Respiratory Research    Vol 3 No 1 McKay and Sharma
Page 6 of 13
(page number not for citation purposes)
Table 4
Airway smooth muscle (ASM) cell-derived growth factors, their target cells and effects
Growth factor Target Effect Reference
FGF-2 ASM Proliferation↑ [38,39]
ECM Collagenase↑
Fibroblast Proliferation↑
PDGF ASM Proliferation↑, IL-6 secretion↑ [38,47,48,72]
Fibroblast Recruitment and proliferation↑
Epithelial cell Proliferation↑
IGF-2 Fibroblast Collagen↑ [38,49]
ASM Proliferation↑
TGF-β1 ASM Proliferation, hypertrophy↑ [21,38,43,44,48]
IL-11, IL-6, LIF secretion↑
β-Adrenergic receptor expression↓
Monocyte Recruitment, NO production↓
Neutrophil Recruitment
Fibroblast Recruitment, proliferation, collagen↑, fibronectin↑
T cells Recruitment
Endothelial cell E-Selectin↓
Eosinophil Survival↓, degranulation↓
VEGF Endothelial cell Proliferation↑, migration, tube formation [50]
↑, Increase; ↓, decrease; ECM, extracellular matrix; FGF-2, fibroblast growth factor-2; IGF-2, insulin-like growth factor-2; IL, interleukin; LIF,
leukaemia inhibitory factor; NO, nitric oxide; PDGF, platelet-derived growth factor; TGF-β, transforming growth factor-β; VEGF, vascular endothelial
growth factor.
potent mitogen for ASM cells and fibroblasts [47,48], and
has been shown to act as a chemoattractant for fibro-
blasts as well as a stimulator for collagenase production
[38]. Vignola et al., however, showed that PDGF-AA,
PDGF-BB and PDGF-AB levels in BAL between controls
and asthmatics were not significantly different [48], infer-
ring that PDGF might not play an important role in the
remodelling of asthmatic airways, although it may be
involved in fibrotic diseases of the lung.
Insulin-like growth factor (IGF)-2 and IGF binding protein-
2 have also been detected in the conditioned medium of
confluent ASM cell cultures [49]. IGF is a mitogen for
these cells, and IGF binding protein-2 modulates the
bioavailability of IGF by binding to it and thereby decreas-
ing its mitogenic potency. IGF expression is not increased
in the airways of asthmatics. In our laboratory, we more
recently found that bronchial ASM cells are capable of
expressing and releasing vascular endothelial growth
factor, an angiogenic peptide, following stimulation with
TNF-α, angiotensin II or endothelin-1 (unpublished data).
These results suggest that ASM cells may be involved in
the regulation of vascular remodelling in the airway wall
during inflammation [50]. Furthermore, these growth
factors may form a link between airway inflammation and
airway and vascular remodelling. Subsequent to hyperpla-
sia and/or hypertrophy, ASM cells remaining in the syn-
thetic/secretory phenotype may further undergo increased
production of inflammatory mediators.
COX products in the airway
COX is the enzyme that converts arachidonic acid to
prostaglandins (PGs), prostacyclin (PGI2) and thrombox-
ane (TX) A2. COX-1 is the constitutively expressed
isoform involved in the production of PGs under physio-
logical conditions. The inducible isoform, COX-2, is
expressed in response to pro-inflammatory stimuli, sug-
gesting it may play a role in the pathophysiology of
asthma. Several studies have shown that ASM cells can
express COX-2 and release PGE2, and to a lesser extent
PGI2, and also the pro-inflammatory TXB2, PGF2α and
PGD2 in response to pro-inflammatory cytokines [51,52].
The relative contribution of the individual COX products
on airway inflammation depends ultimately on the pres-
ence of their respective receptors on target tissues
(Table 5).
PGE2 production by ASM cells can be upregulated in the
presence of pro-inflammatory mediators such as
bradykinin, IL-1β and TNF-α [51,52], but also by β-adreno-
ceptor agonists, IFN-γ and agents that elevate cAMP
levels [53]. Important anti-inflammatory effects of ASM
cell-derived PGE2 include inhibition of mast cell mediator
release, eosinophil chemotaxis and survival, IL-2 and IgE
production by lymphocytes [54], inhibition of ASM cell
mitogenesis [55,56] and inhibition of GM-CSF release by
ASM cells [52]. These studies support the notion that a
negative feedback mechanism exists to limit the inflamma-
tory response. However, PGs also have the ability to
induce bronchoconstriction, to increase mucous secretion
from bronchial wall explants and to enhance airway
responsiveness. TXB2, a pro-inflammatory and bron-
choconstricting mediator, can also be expressed by ASM
cells [51]. It has been demonstrated to have mitogenic
activity on ASM cells and it can trigger cysteinyl-
leukotriene synthesis [57]. TX has also been implicated in
airway hyper-responsiveness [58].
Cytokine-induced COX-2 activity can be inhibited by the
anti-inflammatory steroid dexamethasone, and by non-
steroidal anti-inflammatory drugs [51]. The potential thera-
peutic effects are complicated, however, because the
Available online http://respiratory-research.com/content/3/1/11
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Table 5
Airway smooth muscle (ASM) cell-derived arachidonic acid metabolites, their target cells and effects
Cyclooxygenase product Target Effect Reference
PGD ASM Contraction [9,87,88]
Goblet cell Mucous secretion↑
PGE ASM Contraction, proliferation↓ GM-CSF secretion↓ [9,52,56]
Goblet cell Mucous secretion↑
Mast cell Secretion↓
Eosinophil Recruitment and survival↓
T cell IL-2 secretion↓
PGF ASM Contraction [9,87]
Goblet cell Mucous secretion↑
Thromboxane ASM Contraction and proliferation↑ [57,89]
↑, Increase; ↓, decrease; GM-CSF, granulocyte/macrophage-colony stimulating factor; IL, interleukin; PG = prostaglandin.
consequences of COX-2 induction and PG production
may be beneficial or deleterious. PGE2 is an important
anti-inflammatory mediator and, at low concentrations, it
acts as a bronchodilator, whereas higher concentrations
can lead to bronchoconstriction via the TX receptor.
Lipoxygenase products
5-lipoxygenase (5-LO) is the enzyme that converts arachi-
donic acid to leukotriene (LT) A4, which is quickly con-
verted to LTC4, LTB4, LTD4 and LTE4. The cysteinyl LTC4,
LTD4 and LTE4 are known to mediate bronchoconstriction.
Expression of mRNA for enzymes of the 5-LO pathway (5-
LO, epoxide hydrolase, LTC4 synthase and γ-glutamyl
transpeptidase) by ASM has also been reported following
exposure of ASM cells to atopic serum or IL-1β [59].
Products of 5-LO can cause tissue oedema and migration
of eosinophils, and it can stimulate airway secretions.
LTD4 can also stimulate ASM cell proliferation [60].
Whether, under pathological conditions, ASM cells gener-
ate relevant amounts of LTs remains to be shown.
T-cell interactions with ASM cells
It is well known that adhesion of lymphocytes to endothelial
cells, mediated by adhesion molecules and integrins, is
necessary for their migration from the blood circulation to
areas of tissue injury [6]. The subsequent interactions of
the T lymphocytes with ASM cells in the bronchial mucosa
have also been investigated [61,62]. These studies
showed that ASM cells constitutively express high levels of
CD44, the principal cell surface receptor for hyaluronate,
and express intercellular adhesion molecule-1 and vascular
cell-adhesion molecule-1 when stimulated with TNF-α.
Interactions between ASM cells and activated T lympho-
cytes, possibly via specific adhesion molecules, have been
shown to stimulate ASM cell DNA synthesis and the sub-
sequent ASM cell hyperplasia involved in airway wall
remodelling in inflamed airways. Adherence of anti-CD3-
stimulated peripheral blood T cells to ASM cells markedly
upregulated intercellular adhesion molecule-1 expression
as well as the expression of MHC class II antigens. IFN-γ
stimulation also induced the expression of MHC class II
antigens by ASM cells. These studies suggest that ASM
cells may also act as antigen-presenting cells for pre-acti-
vated T lymphocytes in the asthmatic airways. However,
the ASM cells were unable to support the proliferation of
resting CD4+ T cells by presenting alloantigen [61,62].
Therapeutic intervention for airway
inflammation
A large number of cells in the airways, such as
eosinophils, mast cells, lymphocytes, neutrophils and ASM
cells, contribute to the pathogenesis of inflammatory
airway diseases. Here we specifically discuss potential
anti-inflammatory interventions that target ASM-driven
inflammation.
As mentioned earlier, ASM cells are potential targets for
glucocorticosteroid therapy. Other workers and ourselves
have recently demonstrated that the expression and secre-
tion of pro-inflammatory cytokines and chemokines by
ASM cells in vitro can be inhibited by glucocorticosteroid
treatment [11,12,17,25,26,32,36,40]. COX-2 induction
and the resulting production of arachidonic acid metabo-
lites could similarly be inhibited by treatment with dexa-
methasone [13,51]. Suppression of the COX-2 pathway,
on the contrary, may result in deleterious consequences
considering the bronchoprotective properties of PGE2 in
asthmatic airways.
Mechanistically, it has been proposed that glucocorticoid
receptors interact with transcription factors such as acti-
vator protein-1 and nuclear factor-κB, that are activated by
inflammatory signals. Protein–protein complexes thus
formed prevent DNA binding and subsequent transcrip-
tion of pro-inflammatory cytokines that amplify inflamma-
tion, chemokines involved in recruitment of eosinophils,
inflammatory enzymes that synthesise mediators and
adhesion molecules involved in the trafficking of inflamma-
tory cells to sites of inflammation. Corticosteroids may
also control airway inflammation by increasing the tran-
scription of anti-inflammatory genes like IL-10, IL-12 or IL-
1 receptor antagonist, the gene products of which appear
to be the most potent anti-inflammatory drugs for use in
the treatment of airway inflammation [63].
Stewart et al. have demonstrated that pretreatment with
dexamethasone, methylprednisolone and hydrocortisone
can inhibit serum-induced, FGF-2-induced and thrombin-
induced human ASM cell proliferation [40]. Beclometha-
sone and cortisol were also found to inhibit bovine ASM
cell proliferation in culture [64]. In view of the complexity
of the mechanisms involved in airway inflammation,
however, a treatment for the inhibition or reversal of airway
wall remodelling has yet to be fully validated [65]. In addi-
tion, inhibition of metalloproteinases and growth factors
during glucocorticosteroid therapy may eventually lead to
the persistence of chronic inflammation by preventing
proper wound healing, and thus may indirectly enhance
airway remodelling.
Novel therapies aimed at reducing the effects of (ASM-
derived) chemokines and IL-5 include chemokine receptor
antagonists and IL-5 antagonists [23,66]. A methionine
extension on the amino terminus of RANTES and the mod-
ified form of macrophage inflammatory protein-4, met-
chemokine β7, have been shown to interfere with CCR1
and CCR3 chemokine receptors, thereby inhibiting
eosinophil chemotaxis in animal models of airway inflam-
mation and allergy. However, a multi-mechanistic
approach would probably be advantageous for the treat-
ment of airway inflammation due to the large number of
chemokines and the promiscuous binding pattern for
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multiple receptors (redundancy), making it unlikely that a
single chemokine or chemokine receptor approach would
be beneficial [23].
Similar to the use of chemokine receptor antagonists, the
IL-5 antagonist approach should result in decreased
eosinophilia in inflamed airways. Anti-IL-5 antibodies were
effective in animal models to abrogate eosinophilia, sug-
gesting that the IL-5 receptor is a potential drug target
[66]. A 19-amino acid peptide that binds to the IL-5
receptor alpha/beta heterodimer complex, with an affinity
equal to that of IL-5, has been shown to be a potent and
specific antagonist of IL-5 activity in a human eosinophil
adhesion assay [67]. However, this IL-5 antagonist has
not yet been tested in vivo.
Our increasing knowledge of the intercellular communica-
tion between structural and infiltrating inflammatory cells in
the airways and in view of the role of various cytokines,
chemokines and other inflammatory mediators, provides
an insight into the complex inflammatory processes and
that may subsequently help us to identify novel therapeutic
targets.
Consequences for ongoing airway
inflammation
Allergic airway inflammation develops following the uptake
and processing of inhaled allergens by antigen-presenting
cells such as dendritic cells and macrophages. The subse-
quent interactions between these cells, T lymphocytes
and resident cells leads to a cascade of events contribut-
ing to chronic inflammation, bronchospasm, mucus secre-
tion, oedema and airway remodelling.
The contemporary viewpoint is that the pro-asthmatic
state reflects an imbalance between Th1-type and Th2-
type cytokine production and action, with an upregulated
Th2 cytokine response and a downregulated Th1 cytokine
response [68]. It is postulated that the release of pre-
formed cytokines by mast cells is the initial trigger for the
early infiltration of inflammatory cells (including T cells) into
the airways, and that their subsequent activation and the
release of pro-inflammatory mediators induces airway
hyper-reactivity and recruitment of further inflammatory
cells. The recent data showing that ASM cells exposed to
an inflammatory environment can express and secrete
chemokines, Th1-type and Th2-type cytokines and growth
factors thus provide evidence that these structural cells
could regulate airway inflammation by influencing the local
environment within the airway wall.
Prolonged survival of infiltrating inflammatory cells is
thought to be a result of delayed apoptosis (programmed
cell death), a mechanism that would normally limit tissue
injury during inflammation and promote resolution rather
than progression of inflammation. Both GM-CSF and IL-5
can reduce eosinophil apoptosis, resulting in persistence
of the inflammatory infiltrate and even more tissue
damage. The numerous chemokines secreted by ASM
cells amplify this effect by recruiting more inflammatory
cells to the airway wall (Fig. 1).
TGF-β1, however, can inhibit eosinophil survival and degran-
ulation, and may therefore play a role in the resolution of
inflammation by stimulating the development of post-inflam-
matory repair processes in the airways [69]. The pro-inflam-
matory cytokine-induced release of PGE2 by ASM cells may
also limit the inflammatory response through a mechanism
whereby the secretion of GM-CSF and possibly other
cytokines is inhibited [52]. It should be noted that mast cell
products may have anti-inflammatory properties. Heparin
and heparan sulphate can modulate cell differentiation,
ASM cell proliferation and inflammation [56,65].
Consequences for airway remodelling
The continuous process of healing and repair, due to
chronic airway inflammation, can lead to airway wall
remodelling [4,70,71]. The release of cytokines,
chemokines and growth factors by ASM cells exposed to
an inflammatory environment can result in ASM cell and
goblet cell hyperplasia and/or hypertrophy [21,38,39,43,
44,47,48,71,72]. Proliferation of fibroblasts and the sub-
sequent deposition of ECM components also contribute
to airway wall thickening [71]. Components of the ECM
can form a reservoir for cytokines and growth factors.
Upregulation of tissue inhibitor of metalloproteinase
expression can inhibit the degradation of ECM compo-
nents, resulting in an amplification of this effect. The
increase in airway wall thickness can increase bronchial
hyper-responsiveness and profoundly affect airway nar-
rowing, with a subsequent increase in resistance to airflow
caused by smooth muscle shortening [3].
Consequences for ASM physiology
The recent study by Hakonarson et al. [7] showed that
cytokine exposure can influence ASM contractile function.
They demonstrated that passive sensitisation of ASM
strips augments constrictor responses and reduces relax-
ation responsiveness. These effects are ablated by expo-
sure to the Th1-type cytokines, IL-2 and IFN-γ.
Furthermore, exposure of naïve ASM strips to IL-5 and
GM-CSF (Th2-type cytokines) increased muscarinic
responsiveness and impaired ASM relaxation to the β-
agonist isoproterenol. This study suggests that ASM con-
tractile function can be modulated in an autocrine fashion
during an inflammatory episode.
Work from Stephens et al. shows that ragweed pollen-
sensitised canine bronchial smooth muscle displayed
altered contractile phenotypes when compared with con-
trols, with increased muscle shortening at maximum veloc-
ity. ASM cells obtained from asthmatic patients also
Available online http://respiratory-research.com/content/3/1/11
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showed increased shortening compared with controls
[73]. Such increased muscle shortening could be attrib-
uted to enhanced activity of actin-activated myosin Mg2+-
ATPase.
Increased quantity and activity of myosin light chain
kinase, thereby increasing the actomyosin cycling rate,
was also reported [74]. TGF-β exposure has been
reported to activate myosin light chain kinase, indicating
that stimuli present in inflamed airways may be able to
influence actin–myosin cycling [75]. Hautmann et al.
showed that TGF-β exposure also increases smooth
muscle α-actin, smooth muscle myosin heavy chain and
h1-calponin mRNA in ASM cells in vitro [76].
A recent review by Solway discusses in more detail the
mechanisms whereby a variety of inflammatory stimuli,
such as TNF-α, lysophosphatidic acid and smooth muscle
mitogens, could enhance the actomyosin cycling rate in
ASM cells, thereby influencing ASM physiology in chroni-
cally inflamed asthmatic airways [77].
Concluding remarks
Chronic persistent asthma is still a major health problem
causing morbidity and mortality despite the widespread
use of anti-inflammatory drugs, suggesting a clear need to
develop new therapeutic strategies; in particular, to tackle
structural and functional changes in the airway wall. The
expression and secretion of cytokines, chemokines and
growth factors by ASM cells in vitro support the notion
that ASM cells are actively involved in the inflammatory
response in the airway. These biologically active multipo-
tent mediators can act to alter ASM contractility and prolif-
erative responses as well as exaggerating or dampening
Respiratory Research    Vol 3 No 1 McKay and Sharma
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Figure 1
Schematic diagram depicting the role of airway smooth muscle (ASM) cell-derived mediators in airway inflammation. The release of cytokines,
chemokines or growth factors (open arrows) can result in ASM as well as inflammatory cell proliferation (dark grey arrows), or the recruitment (light
grey arrows) or activation (black arrows) of various cells in the airways. ECM, Extracellular membrane; FGF-2, fibroblast growth factor-2; GM-CSF,
granulocyte/macrophage-colony stimulating factor; IGF-2, insulin-like growth factor-2; IFN, interferon; IL, interleukin; LIF, leukaemia inhibitory factor;
MCP, monocyte chemotactic protein; PDGF, platelet-derived growth factor; PG, prostaglandin; RANTES, regulated on activation, normal T cell
expressed and secreted; TGF-β, transforming growth factor-β; TX, thromboxane.
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the inflammatory response by amplifying signals generated
by infiltrating inflammatory cells. The interaction between
structural ASM cells and cells recruited from the circula-
tion should be further explored to understand this complex
cellular cross-talk and to further define the contributions of
the cellular and molecular events involved in the pathogen-
esis of airway diseases.
Whether the endogenous generation of inflammatory
mediators by ASM cells enhances ASM hyper-responsive-
ness, alters ASM function or supports airway remodelling
in vivo remains to be elucidated. Although the emerging
data from various laboratories implicates a regulatory role
for the ASM in airway inflammatory responses, there is a
clear need to explore the synthetic properties of these
cells. Determination of secretory profiles of chemokines,
cytokines and growth factors by ASM cells would give us
an insight into the complex mechanisms contributing to
chronic airway inflammation and eventually help us identify
potential targets for future drug therapy.
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